Neuren Prescription drugs Restricted (NURPF) Discusses Share Buyback Program, Monetary Place, and Improvement Technique for NNZ-2591 Transcript

Gerry Zhao
Chief Enterprise Officer

Good morning, and welcome to Neuren’s investor webinar to debate our just lately introduced enterprise updates. My title is Gerry Zhao, Chief Enterprise Officer at Neuren. Becoming a member of me in the present day on the decision are — Patrick Davies, Chairman; and Jon Pilcher, Chief Govt Officer. Patrick and Jon will current adopted by a Q&A session. [Operator Instructions]

Earlier than we start, please word that in the present day’s webinar will embody forward-looking statements, that are topic to dangers and uncertainties which will result in totally different outcomes. I am going to now hand over to Jon to start the presentation.

Jonathan Pilcher
CEO, MD & Govt Director

Thanks, Gerry. Good morning, everybody. Thanks very a lot for becoming a member of us in the present day. So this is the agenda of what we’ll undergo. So in a minute, Patrick will begin with some feedback in regards to the share buyback program that we introduced final evening. Then I’ll simply give a recap on the 4 gadgets of stories from final week and provides slightly bit of additional commentary round these. After which I’ll end by only a recap on our general technique for 2591 and why we’re prioritizing what we’re prioritizing.

So there’s lots to get by way of. We clearly need to go away a while for questions. So we’ll transfer fairly quickly. And once we come to the Q&A, relying on the time, if we’re struggling for time, then we’ll prioritize questions which are related to this content material in the present day. So let’s get going. I am going to go to Patrick, please, to simply discuss how we, as a Board, have thought of issues earlier than activating the share buyback.